Pure Global
NCT06365801

Investigation of Acupoint in Irritable Bowel Syndrome Based on Biological Characteristics

Investigation of Acupoint in Irritable Bowel Syndrome Based on Biological Characteristics: A Prospective Cohort Study
The Third Affiliated hospital of Zhejiang Chinese Medical University·ClinicalTrials.govNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Irritable Bowel Syndrome
Study type
Observational
Sponsor & location
Primary sponsor
The Third Affiliated hospital of Zhejiang Chinese Medical University
Timeline & enrollment
Phase
N/A
Start date
Apr 01, 2024
End date
Dec 01, 2025
Enrollment
100 participants
Primary outcome

Pain sensitivity,Thermal radiation characteristics,Microcirculation characteristics,Electrical characteristics,Biological ultra-weak luminescence

Summary

Irritable bowel syndrome (IBS) is a common functional disorder of the digestive system
 characterized by recurrent abdominal pain associated with bowel movements or changes in bowel
 habits. Although there are reviews and guidelines for treating IBS, the complexity and
 diversity of IBS manifestations make treatment difficult. By detecting and exploring the
 biological characteristics presented by the relevant meridian point reaction, this project
 clarified the specificity and regularity of the connection between the acupoint and the
 Zangfu reflected by this phenomenon, and conducted correlation analysis based on the
 intestinal flora, tryptophan metabolite levels and related scales of patients with IBS.

ICD-10 classifications
Irritable bowel syndromeOther and unspecified irritable bowel syndromeIrritable bowel syndrome with mixed bowel habits [IBS-M]Irritable bowel syndrome with predominant constipation [IBS-C]Irritable bowel syndrome with predominant diarrhoea [IBS-D]
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06365801
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06365801 through Pure Global AI's free database. This phase not specified trial is sponsored by The Third Affiliated hospital of Zhejiang Chinese Medical University and is currently Not yet recruiting. The study focuses on Irritable Bowel Syndrome. Target enrollment is 100 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.